|
humans |
21 |
|
medical sciences |
20 |
|
female |
19 |
|
male |
19 |
|
stroke |
19 |
|
atrial fibrillation |
18 |
|
adiponectin |
17 |
|
adult |
16 |
|
middle aged |
16 |
|
hypertension |
14 |
|
blood pressure |
13 |
|
myocardial infarction |
13 |
|
neuromyelitis optica |
13 |
|
recurrence |
13 |
|
alzheimer's disease |
12 |
|
adolescent |
11 |
|
intracranial hemorrhage |
11 |
|
aged |
10 |
|
anisotropy |
10 |
|
gastrointestinal haemorrhage |
10 |
|
intracerebral hemorrhage |
10 |
|
ischemic stroke |
10 |
|
multiple sclerosis |
10 |
|
mutation |
10 |
|
time in therapeutic range |
10 |
|
age factors |
9 |
|
endothelial function |
9 |
|
family health |
9 |
|
garlic |
9 |
|
neuroinflammation |
9 |
|
treatment outcome |
9 |
|
type 2 diabetes mellitus |
9 |
|
aerosolised |
8 |
|
ampk |
8 |
|
anosmia |
8 |
|
aβ |
8 |
|
blood pressure variability |
8 |
|
brain - pathology |
8 |
|
cardiovascular and cerebrovascular diseases |
8 |
|
cha2ds2-vasc |
8 |
|
chads2 |
8 |
|
classical multiple sclerosis |
8 |
|
cognitive impairments |
8 |
|
follow-up studies |
8 |
|
functional brain network |
8 |
|
insulin resistance |
8 |
|
intracranial hemorrhages |
8 |
|
long covid |
8 |
|
mortality |
8 |
|
olfactory dysfunction |
8 |
|
olfactory training |
8 |
|
resting-state fmri |
8 |
|
risk factors |
8 |
|
smell loss |
8 |
|
superoxide dismutase - genetics |
8 |
|
vascular markers |
8 |
|
vascular markers of atherosclerosis |
8 |
|
vitamin a |
8 |
|
young adult |
8 |
|
5' untranslated regions - genetics |
7 |
|
alzheimer’s disease |
7 |
|
antiplatelet medication |
7 |
|
aquaporin-4 autoantibodies |
7 |
|
asian continental ancestry group - ethnology |
7 |
|
cha2ds2-vasc score |
7 |
|
chads2 score |
7 |
|
charcot-marie-tooth |
7 |
|
charcot-marie-tooth disease - genetics - pathology - physiopathology |
7 |
|
child |
7 |
|
chinese |
7 |
|
connexins - genetics |
7 |
|
cutoff |
7 |
|
dna mutational analysis |
7 |
|
electromyography |
7 |
|
genetic diseases, x-linked - genetics |
7 |
|
gjb1 (connexin32) |
7 |
|
hematoma location |
7 |
|
lacunar infarct |
7 |
|
microscopy, electron, transmission |
7 |
|
neural conduction - genetics - physiology |
7 |
|
neuropathy |
7 |
|
non-coding region |
7 |
|
peripheral nerves - pathology - physiopathology - ultrastructure |
7 |
|
point mutation - genetics |
7 |
|
prognosis |
7 |
|
sequence analysis |
7 |
|
stroke outcome |
7 |
|
als |
6 |
|
amyotrophic lateral sclerosis - enzymology - genetics - pathology |
6 |
|
amyotrophic lateral sclerosis - genetics |
6 |
|
antiplatelet agents |
6 |
|
asian continental ancestry group |
6 |
|
aspirin - administration & dosage - adverse effects |
6 |
|
ciliary neurotrophic factor - genetics |
6 |
|
cntf |
6 |
|
coronary artery disease |
6 |
|
diabetes |
6 |
|
diffusion magnetic resonance imaging - methods |
6 |
|
dna mutational analysis - methods |
6 |
|
dti |
6 |
|
exons - genetics |
6 |
|
familial |
6 |
|
familial amyotrophic lateral sclerosis |
6 |
|
glycaemia |
6 |
|
has-bled score |
6 |
|
hba1c variability |
6 |
|
ich volume |
6 |
|
image processing, computer-assisted |
6 |
|
intracranial hemorrhages - drug therapy - physiopathology - surgery |
6 |
|
intraventricular extension |
6 |
|
isoleucine - genetics |
6 |
|
mediterranean-style diet |
6 |
|
mutations |
6 |
|
neurological deterioration |
6 |
|
neuromyelitis optica spectrum disorders |
6 |
|
nonsymptomatic |
6 |
|
pedigree |
6 |
|
phenotype |
6 |
|
platelet aggregation inhibitors - administration & dosage - adverse effects |
6 |
|
registries |
6 |
|
reverse transcriptase polymerase chain reaction - methods |
6 |
|
sod1 |
6 |
|
sod1 mutation |
6 |
|
spinal cord - pathology |
6 |
|
statistics, nonparametric |
6 |
|
stroke/prevention |
6 |
|
threonine - genetics |
6 |
|
vascular endothelial growth factor a - genetics |
6 |
|
vegf |
6 |
|
visit-to-visit blood pressure variability |
6 |
|
warfarin |
6 |
|
warfarin-associated ich |
6 |
|
animals |
5 |
|
autoantibodies - blood |
5 |
|
autoimmune encephalitis |
5 |
|
beta deposition |
5 |
|
cervical spinal cord |
5 |
|
dentate gyrus |
5 |
|
diffusion tensor imaging |
5 |
|
diffusion tensor imaging - methods |
5 |
|
follow-up |
5 |
|
free radicals |
5 |
|
hong kong |
5 |
|
insulin-resistance |
5 |
|
limbic encephalitis |
5 |
|
mitochondrial dysfunction |
5 |
|
neuromyelitis optica - diagnosis - pathology |
5 |
|
neuroprotection |
5 |
|
optic neuritis |
5 |
|
oxidative stress |
5 |
|
paraneoplastic syndrome |
5 |
|
possible involvement |
5 |
|
retrospective studies |
5 |
|
secondary prevention |
5 |
|
survivors |
5 |
|
ucp4 |
5 |
|
uncoupling proteins |
5 |
|
1-methyl-4-phenylpyridinium - metabolism |
4 |
|
1-methyl-4-phenylpyridinium - toxicity |
4 |
|
abbreviated metal test |
4 |
|
acquired myasthenia gravis |
4 |
|
adenosine triphosphate - genetics - metabolism |
4 |
|
adenosine triphosphate - metabolism |
4 |
|
adult cardiology |
4 |
|
aged, 80 and over |
4 |
|
alzheimers disease assessment scale cognitive subscale |
4 |
|
amyloid beta protein |
4 |
|
amyotrophic lateral sclerosis |
4 |
|
angiography, digital subtraction |
4 |
|
antibodies - immunology |
4 |
|
apoptosis |
4 |
|
aquaporin 4 - biosynthesis - genetics |
4 |
|
aquaporin 4 - immunology |
4 |
|
aquaporin-4 water channel |
4 |
|
atp |
4 |
|
autoimmune |
4 |
|
autoimmune diseases of the nervous system - immunology |
4 |
|
azathioprine |
4 |
|
benign paroxysmal positional vertigo |
4 |
|
bronchial epithelium |
4 |
|
cell fractionation |
4 |
|
cell line |
4 |
|
cell line, tumor |
4 |
|
cell survival |
4 |
|
cerebellar hemorrhages |
4 |
|
cerebrovascular circulation |
4 |
|
cervical vertebrae |
4 |
|
chi-square distribution |
4 |
|
clinical outcome |
4 |
|
cloning, molecular |
4 |
|
compute tomography |
4 |
|
cross-sectional studies |
4 |
|
cytoprotection |
4 |
|
demyelinating diseases - immunology |
4 |
|
dermatomyositis - etiology - therapy |
4 |
|
diffusional kurtosis imaging |
4 |
|
dopamine |
4 |
|
dopamine - metabolism |
4 |
|
dopamine - pharmacology |
4 |
|
endothelin-1 |
4 |
|
enzyme linked immunosorbent assay |
4 |
|
epidemiologic studies |
4 |
|
epidemiology |
4 |
|
expand disability status scale |
4 |
|
expanded disability status scale score |
4 |
|
experimental allergic encephalomyelitis |
4 |
|
fever of unknown origin - microbiology - radiography |
4 |
|
fluorescent antibody technique, indirect |
4 |
|
gene delivery |
4 |
|
glycolysis - drug effects |
4 |
|
herbicides - toxicity |
4 |
|
hong kong - epidemiology |
4 |
|
hong kong chinese |
4 |
|
idiopathic inflammatory demyelinating disorders |
4 |
|
idiopathic relapsing transverse myelitis |
4 |
|
immunization |
4 |
|
immunodominant epitopes - chemistry - immunology |
4 |
|
immunoglobulin g - blood |
4 |
|
immunosuppressant therapy |
4 |
|
incidence |
4 |
|
inflammatory demyelinating disorders |
4 |
|
ion channels - genetics - metabolism |
4 |
|
ion channels - genetics - physiology |
4 |
|
leptin - pharmacology |
4 |
|
logistic models |
4 |
|
long-term outcome |
4 |
|
longitudinally extensive transverse myelitis |
4 |
|
lung function |
4 |
|
lymphatic metastasis |
4 |
|
magnetic resonance imaging - methods |
4 |
|
membrane potential, mitochondrial |
4 |
|
membrane potential, mitochondrial - drug effects |
4 |
|
membrane transport proteins - genetics - immunology - metabolism |
4 |
|
membrane transport proteins - genetics - metabolism |
4 |
|
minimally conscious state |
4 |
|
mitochondria |
4 |
|
mitochondria - drug effects - metabolism |
4 |
|
mitochondria - genetics - immunology - metabolism |
4 |
|
mitochondrial membrane potential |
4 |
|
mitochondrial proteins - genetics - metabolism |
4 |
|
mitochondrial proteins - genetics - physiology |
4 |
|
motor neuron disease |
4 |
|
motor neuron disease - diagnosis - epidemiology |
4 |
|
motor neuron disease - etiology - therapy |
4 |
|
mpp + |
4 |
|
mpp+ |
4 |
|
multiple sclerosis - immunology |
4 |
|
myasthenia gravis |
4 |
|
myasthenia gravis - immunology - metabolism - pathology |
4 |
|
myelitis, transverse - immunology |
4 |
|
myositis - etiology - therapy |
4 |
|
nasopharyngeal carcinoma |
4 |
|
nasopharyngeal neoplasms - complications |
4 |
|
neoplasm recurrence, local - complications - therapy |
4 |
|
nerve tissue proteins - genetics - metabolism |
4 |
|
neuromyelitis optica - immunology |
4 |
|
neuromyelitis optica-igg |
4 |
|
neurons - drug effects - metabolism - pathology |
4 |
|
neurons - immunology - metabolism - pathology |
4 |
|
neuroprotective agents - pharmacology |
4 |
|
nicotine |
4 |
|
nicotinic acetylcholine receptor |
4 |
|
nlrp3 |
4 |
|
normal-appearing brain tissues |
4 |
|
optic neuritis - immunology |
4 |
|
oxidative phosphorylation |
4 |
|
oxidative stress - drug effects |
4 |
|
paraneoplastic inflammatory myopathy |
4 |
|
paraneoplastic motor neuropathy |
4 |
|
paraneoplastic neurological disorders |
4 |
|
paraneoplastic syndromes - etiology - therapy |
4 |
|
parkinson disease |
4 |
|
peptides - administration & dosage - chemical synthesis |
4 |
|
pregnancy |
4 |
|
pregnancy complications, infectious - etiology - radiography |
4 |
|
prevalence |
4 |
|
proinflammatory cytokines |
4 |
|
protein blood level |
4 |
|
psychiatry and neurology |
4 |
|
quantitative polymerase chain reaction |
4 |
|
relapsing remitting multiple sclerosis |
4 |
|
rna, small interfering |
4 |
|
secondary progression multiple sclerosis |
4 |
|
sex factors |
4 |
|
sheep |
4 |
|
standard deviation |
4 |
|
superoxides - metabolism |
4 |
|
telemedicine |
4 |
|
th1 cells |
4 |
|
th17 cells |
4 |
|
thymoma |
4 |
|
thymoma - immunology - metabolism - pathology |
4 |
|
thymus neoplasms - immunology - metabolism - pathology |
4 |
|
tomography, x-ray computed - methods |
4 |
|
transgenes - genetics |
4 |
|
tuberculoma - complications - radiography |
4 |
|
tuberculosis, meningeal - complications - radiography |
4 |
|
ucp |
4 |
|
β-interferon |
4 |
|
acetylcholine receptor autoantibodies |
3 |
|
acute disease |
3 |
|
acute transverse myelitis |
3 |
|
affective symptoms - etiology |
3 |
|
age of onset |
3 |
|
anti-coagulation |
3 |
|
anti-inflammatory agents - therapeutic use |
3 |
|
anticoagulants - therapeutic use |
3 |
|
antihypertensive agents - adverse effects - pharmacology - therapeutic use |
3 |
|
antioxidants - metabolism |
3 |
|
antiparkinson agents - therapeutic use |
3 |
|
antiviral agents - therapeutic use |
3 |
|
aquaporin 4 - antagonists and inhibitors - deficiency - genetics - immunology |
3 |
|
asian continental ancestry group - statistics & numerical data |
3 |
|
astrocyte activation |
3 |
|
astrocytes - immunology - metabolism - pathology |
3 |
|
autoantibodies - analysis - immunology |
3 |
|
autoantibodies - toxicity |
3 |
|
autoimmunity |
3 |
|
bath-related headache |
3 |
|
baths - adverse effects |
3 |
|
biological evolution |
3 |
|
brain - blood supply |
3 |
|
brain - pathology - virology |
3 |
|
brain - physiology |
3 |
|
brain edema - etiology |
3 |
|
brain ischemia - etiology - physiopathology |
3 |
|
brainstem |
3 |
|
brainstem atrophy |
3 |
|
brainstem regional volume |
3 |
|
bromocriptine - therapeutic use |
3 |
|
bronchial epithelial cells |
3 |
|
c-rel |
3 |
|
carotid artery, internal - radiography |
3 |
|
cerebral angiography |
3 |
|
cerebral arteries - metabolism |
3 |
|
cerebral haemorrhage |
3 |
|
cerebral infarction |
3 |
|
cerebral infarction - etiology - radiography |
3 |
|
cerebral venous thrombosis |
3 |
|
chelating agents - therapeutic use |
3 |
|
child, preschool |
3 |
|
chrna7 |
3 |
|
cigarette smoke |
3 |
|
cognition - physiology |
3 |
|
complement activation |
3 |
|
confusion - etiology |
3 |
|
corticosteroid |
3 |
|
demyelinating autoimmune diseases, cns - immunology |
3 |
|
demyelinating diseases - diagnosis - etiology - therapy |
3 |
|
demyelinating diseases - immunology - metabolism - pathology |
3 |
|
demyelinating disorders |
3 |
|
depression |
3 |
|
depressive disorder - complications - pathology - psychology |
3 |
|
dexamethasone - therapeutic use |
3 |
|
diabetes complications - etiology |
3 |
|
diagnosis, differential |
3 |
|
diffusion magnetic resonance imaging |
3 |
|
digital subtraction angiography |
3 |
|
disability |
3 |
|
disease progression |
3 |
|
early-onset myasthneia gravis |
3 |
|
encephalitis |
3 |
|
encephalitis, herpes simplex - pathology |
3 |
|
energy homeostasis |
3 |
|
environment |
3 |
|
epilepsy, generalized - etiology |
3 |
|
equipment design |
3 |
|
european continental ancestry group - genetics |
3 |
|
fatal outcome |
3 |
|
fever - etiology |
3 |
|
fluorescent antibody technique, indirect - methods |
3 |
|
frontal lobe - pathology |
3 |
|
gene expression regulation, developmental - genetics |
3 |
|
guillain-barre syndrome |
3 |
|
guillain-barré syndrome |
3 |
|
headache |
3 |
|
headache - diagnosis - etiology - therapy |
3 |
|
headache - etiology |
3 |
|
heparin, low-molecular-weight - therapeutic use |
3 |
|
hepatitis e |
3 |
|
hepatitis e virus |
3 |
|
hepatolenticular degeneration - complications - pathology - psychology |
3 |
|
hypertension - complications - drug therapy |
3 |
|
idiopathic inflammatory |
3 |
|
idiopathic transverse myelitis |
3 |
|
infarction, middle cerebral artery - etiology - physiopathology - radiography - surgery |
3 |
|
infarction, posterior cerebral artery - etiology - physiopathology |
3 |
|
intelligence - genetics |
3 |
|
intracranial arteriosclerosis - complications |
3 |
|
intracranial arteriosclerosis - genetics |
3 |
|
intracranial hemorrhages - etiology - pathology - physiopathology |
3 |
|
intracranial thrombosis - complications |
3 |
|
intracranial thrombosis - complications - pathology - physiopathology |
3 |
|
large artery infarct |
3 |
|
late-onset myasthenia gravis |
3 |
|
life style |
3 |
|
lung cancer |
3 |
|
magnetic resonance imaging |
3 |
|
magnetic resonance imaging (mri) |
3 |
|
microglia |
3 |
|
middle cerebral artery - radiography |
3 |
|
models, biological |
3 |
|
motor endplate - metabolism |
3 |
|
mouse |
3 |
|
multiple sclerosis (ms) |
3 |
|
muscle, skeletal - metabolism |
3 |
|
myasthenia gravis - diagnosis - epidemiology - therapy |
3 |
|
myelin |
3 |
|
myelin sheath - pathology |
3 |
|
myelitis, transverse - complications - diagnosis - physiopathology - therapy |
3 |
|
myelitis, transverse - diagnosis - etiology - therapy |
3 |
|
myopia - genetics |
3 |
|
nephrotic syndrome - complications |
3 |
|
nervous system |
3 |
|
neurodegeneration |
3 |
|
neuromyelitis optica - immunology - metabolism - pathology |
3 |
|
neuromyelitis optica spectrum disorders (nmosd) |
3 |
|
nonthymoma-generalized myasthenia gravis |
3 |
|
nuclear factor κb |
3 |
|
nuclear factor-κb |
3 |
|
oriental female |
3 |
|
parkinson's disease |
3 |
|
parkinsonian disorders - complications - pathology - psychology |
3 |
|
parkinsonism |
3 |
|
parkinsons disease |
3 |
|
pd-l1 |
3 |
|
penicillamine |
3 |
|
penicillamine - therapeutic use |
3 |
|
plasmapheresis |
3 |
|
porcine liver |
3 |
|
promoter |
3 |
|
psychiatry and neurology medical sciences |
3 |
|
pulmonary edema - etiology |
3 |
|
radiography, interventional |
3 |
|
receptors, nicotinic - immunology |
3 |
|
relayed nuclear overhauser effect (rnoe) |
3 |
|
seizures - etiology |
3 |
|
selection, genetic |
3 |
|
severity of illness index |
3 |
|
spinal cord |
3 |
|
striated muscle autoantibodies |
3 |
|
substance abuse, intravenous - complications |
3 |
|
suicide, attempted |
3 |
|
surgery |
3 |
|
temporal lobe - pathology |
3 |
|
thrombectomy - instrumentation - methods |
3 |
|
thunderclap headache |
3 |
|
tomography, x-ray computed |
3 |
|
transcription regulation |
3 |
|
trientine - therapeutic use |
3 |
|
trientine hydrochloride |
3 |
|
triggering agents |
3 |
|
trihexyphenidyl - therapeutic use |
3 |
|
tuberculosis, meningeal - complications - drug therapy - radiography |
3 |
|
tuberculous meningitis |
3 |
|
uncoupling protein |
3 |
|
uncoupling protein 4 |
3 |
|
vasoconstriction |
3 |
|
venous thrombosis - complications |
3 |
|
venous thrombosis - complications - pathology - physiopathology |
3 |
|
viral encephalitis |
3 |
|
vision disorders - etiology |
3 |
|
warfarin - therapeutic use |
3 |
|
wernicke encephalopathy - complications - diagnosis |
3 |
|
wilson's disease |
3 |
|
amyloid |
2 |
|
amyloid-related imaging abnormalities |
2 |
|
amyloid-β |
2 |
|
antibodies, viral - analysis |
2 |
|
antitubercular agents - therapeutic use |
2 |
|
aquaporin 4 |
2 |
|
aquaporin-4 |
2 |
|
aria |
2 |
|
arterial spin labeling |
2 |
|
astrocyte |
2 |
|
autoimmune diseases |
2 |
|
axonal damage |
2 |
|
biologics |
2 |
|
blood brain barrier leakage |
2 |
|
caa-ri |
2 |
|
carcinoma, hepatocellular - diagnosis - pathology |
2 |
|
cerebral amyloid angiopathy |
2 |
|
cerebral amyloid angiopathy-related inflammation |
2 |
|
cerebral blood flow |
2 |
|
cerebrospinal fluid |
2 |
|
cerebrovascular disorders - etiology - physiopathology - prevention & control - therapy |
2 |
|
cidp |
2 |
|
circadian rhythm |
2 |
|
circadian rhythm - physiology |
2 |
|
complications |
2 |
|
cryptococcosis |
2 |
|
data collection |
2 |
|
dementia |
2 |
|
demyelination |
2 |
|
ectopic lymphoid structures |
2 |
|
encephalitis - diagnosis - pathology |
2 |
|
encephalocele |
2 |
|
endothelium inflammation |
2 |
|
epilepsy |
2 |
|
experimental autoimmune encephalomyelitis |
2 |
|
germinal center |
2 |
|
growing fracture |
2 |
|
head injury |
2 |
|
hematology |
2 |
|
hiv - immunology |
2 |
|
hong kong - ethnology |
2 |
|
hospitals |
2 |
|
hydrocephalus - cerebrospinal fluid - drug therapy - etiology |
2 |
|
hypertension, malignant - diagnosis |
2 |
|
intracerebral haemorrhage |
2 |
|
intracranial hemorrhages - diagnosis - pathology |
2 |
|
intracranial hypertension - microbiology |
2 |
|
ischaemic stroke |
2 |
|
ischemic attack, transient - mortality - physiopathology |
2 |
|
knowledge |
2 |
|
meningitis, cryptococcal - complications - diagnosis - drug therapy |
2 |
|
miller fisher syndrome - complications - therapy |
2 |
|
myasthenia gravis - etiology |
2 |
|
mycobacterium tuberculosis - isolation & purification |
2 |
|
nervous system diseases - complications |
2 |
|
neuromyelitis optica - classification - pathology |
2 |
|
neuromyelitis optica spectrum disorder |
2 |
|
pparγ |
2 |
|
prospective studies |
2 |
|
rorγt |
2 |
|
sirt1 |
2 |
|
snp |
2 |
|
stroke - complications |
2 |
|
stroke - mortality - physiopathology |
2 |
|
stroke onset |
2 |
|
subjective cognitive decline |
2 |
|
survey |
2 |
|
tag-1 |
2 |
|
th17 cell |
2 |
|
time factors |
2 |
|
transient ischaemic attack |
2 |
|
transplant |
2 |
|
tuberculosis, meningeal - cerebrospinal fluid - complications - drug therapy |
2 |
|
vaccine |
2 |
|
acetylcholine receptor |
1 |
|
achr antibody |
1 |
|
adult-acquired myasthenia gravis |
1 |
|
antibodies, antinuclear - blood |
1 |
|
anticholesteremic agents - adverse effects |
1 |
|
aqp4-igg |
1 |
|
aquaporin-4 autoimmunity |
1 |
|
autoantibodies |
1 |
|
autoantibody evaluation |
1 |
|
autoimmunity - immunology |
1 |
|
b lymphocytes |
1 |
|
beta-interferons (乙型干擾素) |
1 |
|
carcinoma, small cell - blood - immunology |
1 |
|
cyclosporine - adverse effects |
1 |
|
cytomegalovirus infections - complications |
1 |
|
ganglion cell layer |
1 |
|
hepatitis b -- periodicals. |
1 |
|
heptanoic acids - adverse effects |
1 |
|
immunomodulation |
1 |
|
immunosuppressive agents - adverse effects |
1 |
|
interferon -- periodicals. |
1 |
|
lung neoplasms - blood - immunology |
1 |
|
memantine |
1 |
|
mesenchymal stem cells |
1 |
|
multiple sclerosis -- periodicals. |
1 |
|
muscle |
1 |
|
musk antibody |
1 |
|
myasthenia gravis. |
1 |
|
natalizumab |
1 |
|
neural |
1 |
|
optical coherence tomography |
1 |
|
paraneoplastic syndromes, nervous system - blood - immunology |
1 |
|
regulatory b cells |
1 |
|
regulatory t cells |
1 |
|
relapsing-remitting multiple sclerosis (復發緩解型多發性硬化) |
1 |
|
retinal nerve fiber layer |
1 |
|
seronegative myasthenia gravis |
1 |
|
t lymphocytes |
1 |
|
water channel |
1 |
